Mercado europeo de diagnóstico del cáncer de próstata: tendencias de la industria y pronóstico hasta 2028

Personalice su informePersonalice su informe Compre ahoraCompre ahora Ejemplo de informe gratuitoEjemplo de informe gratuito
Hogar Medical Devices Europe Prostate Cancer Diagnostics Market
Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado europeo de diagnóstico del cáncer de próstata: tendencias de la industria y pronóstico hasta 2028

  • Medical Devices
  • Published Report
  • Mar 2021
  • Europe
  • 350 Páginas
  • Número de tablas: 193
  • Número de figuras: 55
Comprar ahoraComprar ahora

Europe Prostate Cancer Diagnostics Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
 2021 –2028
Diagram Tamaño del mercado (año base)
 USD 636.30 Million
Diagram Tamaño del mercado (año de pronóstico)
 USD 1,604.78 Million
Diagram Tasa de crecimiento anual compuesta (CAGR)
 %
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5
Solicitud de desbloqueo

Mercado europeo de medicamentos para el diagnóstico del cáncer de próstata, por tipo de producto (instrumentos, reactivos y consumibles y accesorios), tipo de diagnóstico (pruebas de detección preliminares, pruebas de confirmación), grupo de edad (adultos, niños y geriatría), tipo (adenocarcinoma de próstata, carcinoma de células pequeñas y otros), estadio (cáncer de próstata localizado, cáncer de próstata recurrente/avanzado y cáncer de próstata resistente a la castración (metastásico y no metastásico), tipo de muestra (sangre, tejido, orina y otros), usuarios finales (laboratorios de diagnóstico independientes, hospitales, institutos de investigación del cáncer, clínicas, centros quirúrgicos ambulatorios y otros), canal de distribución (licitación directa y ventas minoristas), país (Alemania, Francia, Reino Unido, Italia, España, Rusia, Turquía, Países Bajos, Suiza, Bélgica y resto de Europa) Tendencias de la industria y pronóstico hasta 2028

Mercado europeo de diagnóstico del cáncer de próstataAnálisis y perspectivas del mercado: mercado europeo de diagnóstico del cáncer de próstata

Se espera que el mercado de diagnóstico de cáncer de próstata gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 12,5% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 1.604,78 millones para 2028 desde USD 636,30 millones en 2020. El aumento del enfoque en la carga de la enfermedad y el aumento de la conciencia sobre la enfermedad son los principales impulsores que están impulsando el mercado en el período de pronóstico.

Para el diagnóstico se utilizan instrumentos, reactivos, consumibles y accesorios. La prueba de PSA, los exámenes rectales digitales, la resonancia magnética, la tomografía por emisión de positrones (PET/CT), entre otros, son algunas de las pruebas preliminares y confirmatorias que se utilizan en el diagnóstico del cáncer de próstata. Se espera que la creciente prevalencia del cáncer de próstata, el aumento de la investigación y el desarrollo en el diagnóstico del cáncer de próstata, el aumento de la población geriátrica y el lanzamiento de nuevos productos para el diagnóstico del cáncer de próstata impulsen el crecimiento del mercado de diagnóstico del cáncer de próstata. Además, el aumento de la inversión y la financiación por parte de actores emergentes, la política de reembolso para el diagnóstico del cáncer de próstata y las iniciativas gubernamentales hacia el diagnóstico del cáncer refuerzan el crecimiento del mercado de diagnóstico del cáncer de próstata.

La demanda de diagnósticos de cáncer de próstata ha aumentado tanto en los países desarrollados como en los países en desarrollo y la razón detrás de esto es el creciente enfoque en la mortalidad por cáncer de próstata. El mercado de diagnóstico de cáncer de próstata está creciendo debido a la introducción de productos innovadores, la creciente conciencia y varias iniciativas gubernamentales. El mercado crecerá en el período previsto debido a la exploración de mercados emergentes, iniciativas estratégicas de los actores del mercado y una mayor conciencia sobre los problemas del cabello.

El informe de mercado de diagnóstico de cáncer de próstata proporciona detalles de la participación de mercado, nuevos desarrollos y análisis de la cartera de productos, el impacto de los actores del mercado nacional y localizado, analiza las oportunidades en términos de bolsillos de ingresos emergentes, cambios en las regulaciones del mercado, aprobaciones de productos, decisiones estratégicas, lanzamientos de productos, expansiones geográficas e innovaciones tecnológicas en el mercado. Para comprender el análisis y el escenario del mercado, contáctenos para obtener un resumen de analistas; nuestro equipo lo ayudará a crear una solución de impacto en los ingresos para lograr su objetivo deseado.

Mercado europeo de diagnóstico del cáncer de próstataAlcance y tamaño del mercado de diagnóstico del cáncer de próstata en Europa

El mercado de diagnóstico de cáncer de próstata se clasifica en ocho segmentos notables que se basan en el tipo de producto, tipo de diagnóstico, grupo de edad, tipo, etapa, tipo de muestra, usuarios finales y canal de distribución.

  • Según el tipo de producto, el mercado de diagnóstico del cáncer de próstata se segmenta en instrumentos, reactivos y consumibles y accesorios. En 2021, el segmento de reactivos y consumibles domina el mercado de diagnóstico del cáncer de próstata, ya que incluye los productos de prueba de PSA, que es la prueba principal recomendada para las pruebas preliminares. El PSA mide la proteína producida por las células de la glándula prostática, que es la primera línea de diagnóstico del cáncer de próstata.
  • Según el tipo de diagnóstico, el mercado de diagnóstico del cáncer de próstata se segmenta en pruebas de detección preliminares y pruebas confirmatorias. En 2021, el segmento de pruebas de detección preliminares domina el mercado de diagnóstico del cáncer de próstata, ya que la cantidad de pruebas preliminares supera la cantidad de pruebas confirmatorias en un porcentaje significativo.
  • En función del grupo de edad, el mercado de diagnóstico del cáncer de próstata se segmenta en adultos, pediátricos y geriátricos. En 2021, el segmento geriátrico domina el mercado de diagnóstico del cáncer de próstata, ya que alrededor del 60% de los casos se diagnostican en hombres mayores de 65 años. La edad promedio de diagnóstico del cáncer de próstata es de 66 años. La enfermedad rara vez se presenta en menores de 40 años. El número de casos nuevos diagnosticados en hombres de raza negra es un 60% mayor que el número de casos nuevos diagnosticados en hombres de raza blanca.
  • Según el tipo, el mercado de diagnóstico del cáncer de próstata se segmenta en adenocarcinoma de próstata, carcinoma de células pequeñas y otros. En 2021, el segmento de adenocarcinoma de próstata domina el mercado de diagnóstico del cáncer de próstata porque más del 95 por ciento de los cánceres de próstata son adenocarcinomas que se desarrollan en las células glandulares y la línea de la glándula prostática. Casi todos los hombres con cáncer de próstata tienen este tipo. Es la segunda causa principal de muerte relacionada con el cáncer en los hombres. Una vez que el cáncer alcanza una determinada etapa, las células anormales se propagan a otras partes del cuerpo, provocando así metástasis, lo que lleva a dominar el segmento del mercado.
  • On the basis of stage, the prostate cancer diagnostics market is segmented into localized prostate cancer, recurrent/advanced prostate cancer and castration-resistant prostate cancer (metastatic and non-metastatic). In 2021, localized prostate cancer segment dominates the prostate cancer diagnostics market as approximately 80 percent to 85 percent of all prostate cancers are detected in the local or regional stages which represent stages I, II and III. Most of the men diagnosed and treated at the local or regional stages will be disease-free after five years. This type of cancer does not spread in any of the nearby tissues or to distant parts of the body. The stages present in localized prostate cancer are stage 1 and 2. The growth of tumor in low-risk localized prostate cancer is slow.
  • On the basis of sample type, the prostate cancer diagnostics market is segmented into blood, tissue, urine and others. In 2021, blood segment is dominating the prostate cancer diagnostics market as blood is the primary sample for the most common preliminary test that is PSA test and due to easy availability of blood, less complex procedure of blood sample collection doesn’t take much time which is expected to dominate the prostate cancer diagnostics market.
  • On the basis of end user, the prostate cancer diagnostics market is segmented into independent diagnostic laboratories, hospitals, cancer research institutes, clinics, ambulatory surgical centers and others. In 2021, Independent diagnostic laboratories segment is dominating the prostate cancer diagnostics market as this segment is specialized in conducting various prostate cancer diagnostics. Moreover, independent diagnostic laboratories enable the facilitation of robust, on-time, cost-effective and high quality diagnostic care and services in safe healthcare environment and are convenient for consulting physician/healthcare institution to outsource bulk diagnostics tests to independent diagnostic laboratories for better customer services.
  • On the basis of distribution type, the prostate cancer diagnostics market is segmented into direct tender and retail sales. In 2021, direct tender segment dominates the prostate cancer diagnostics market as they are the primary source of procurement of reagents, consumables, devices and accessories by healthcare organizations and diagnostic labs. With the increasing cost of healthcare, healthcare service providers are focusing on better services for customers along with reducing the overall cost. The procurement of products through direct tender is highly cost effective for healthcare providers.

Prostate Cancer Diagnostics Market Country Level Analysis

The prostate cancer diagnostics market is categorized into eight notable segments which are based on the product type, diagnostics type, age group, type, stage, sample type, end users and distribution channel.

The countries covered in the prostate cancer diagnostics market report are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe.

Europe is expected to grow with the highest CAGR in the forecasted period as in the growing prevalence of prostate cancer and favorable reimbursement landscape. Germany is expected to dominate in the Europe market primarily due to increasing geriatric population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.  

Strategic Initiatives by manufactures is Creating New Opportunities for Players in the Prostate Cancer Diagnostics Market 

Prostate cancer diagnostics market also provides you with detailed market analysis for every country growth in prostate cancer diagnostics product sales, impact of advancement in the prostate cancer diagnostics and changes in regulatory scenarios with their support for the prostate cancer diagnostics market. The data is available for historic period 2011 to 2019.

Competitive Landscape and Prostate Cancer Diagnostics Market Share Analysis

Prostate cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to prostate cancer diagnostics market.

The major companies providing prostate cancer diagnostics are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, OPKO Health Inc., Abott, Beckman Coulter, Inc. (A Subsidiary of Danaher), among others domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many product launch and agreement are also initiated by the companies’ worldwide which are also accelerating the prostate cancer diagnostics market.

For instance,  

  • En diciembre de 2020, Fujirebio Europe anunció que había recibido una subvención de 876.000 dólares estadounidenses de Flanders Innovation & Entrepreneurship (VLAIO) para desarrollar una plataforma de diagnóstico in vitro (IVD) clínico que incorpore tecnologías de secuenciación de tercera generación (TGS). El objetivo es desarrollar un IVD rentable, preciso y portátil. Esto mejorará el perfil de la empresa y aumentará la investigación y el desarrollo de la misma.

La colaboración, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de diagnóstico del cáncer de próstata, lo que también proporciona el beneficio para que la organización mejore su oferta para el mercado de diagnóstico del cáncer de próstata.

 

 

SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

Sample Image Click on image to enlarge
  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

  1. introduction
    1. OBJECTIVES OF THE STUDY
    2. MARKET DEFINITION
    3. OVERVIEW of EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    4. LIMITATIONs
    5. MARKETS COVERED
  2. MARKET SEGMENTATION
    1. MARKETS COVERED
    2. geographical scope
    3. years considered for the study
    4. currency and pricing
    5. DBMR TRIPOD DATA VALIDATION MODEL
    6. MULTIVARIATE MODELLING
    7. product type LIFELINE CURVE
    8. primary interviews with key opinion leaders
    9. DBMR MARKET POSITION GRID
    10. MARKET end users coverage GRID
    11. vendor share analysis
    12. secondary sourcEs
    13. assumptions
  3. EXECUTIVE SUMMARY
  4. Epidemiology
  5. COMPARATIVE ANALYSIS WITH PARENT MARKET
  6. REGULATORY FRAMEWORK: EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    1. REGULATORY SCENARIO IN EUROPEAN UNION
  7. market overview
    1. drivers
      1. INCREASING PREVALENCE OF PROSTATE CANCER
      2. INCREASE RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTIC
      3. INCREASE IN GERIATRIC POPULATION
      4. LAUNCH OF NEW PRODUCTS FOR PROSTATE CANCER DIAGNOSTIC
      5. DISEASE CAUSING PROSTATE CANCER
    2. RESTRAINTS
      1. CONTROVERSY RELATED TO PSA TESTING
      2. HIGH COST OF DIAGNOSTICS PROCEDURE
      3. LACK OF SKILLED AND CERTIFIED PROFESSIONALS
    3. OPPORTUNITIES
      1. RISING INVESTMENT AND FUNDING BY EMERGING PLAYERS
      2. REIMBURSEMENT POLICY FOR PROSTATE CANCER DIAGNOSIS
      3. GOVERNMENT INITIATIVES TOWARDS CANCER DIAGNOSTICS
      4. RISING SURVIVAL RATE DUE TO EARLY DIAGNOSIS OF PROSTATE CANCER
    4. Challenges
      1. STRINGENT REGULATORY REQUIREMENT FOR DIAGNOSTIC PRODUCTS
      2. OPERATIONAL BARRIERS FACED IN CONDUCTING DIAGNOSTICS TESTS
      3. INACCURATE DIAGNOSIS RESULTS
  8. IMPACT OF COVID-19 ON EUROPE PROSTATE CANCER DIAGNOSTICS MARKET
    1. IMPACT ON PRICE
    2. IMPACT ON DEMAND
    3. IMPACT ON SUPPLY CHAIN
    4. STRATEGIC DECISION BY MANUFACTURERS MADE DURING COVID-19 PANDEMIC
    5. KEY INITIATIVES BY MARKET PLAYERS DURING COVID-19
    6. CONCLUSION
  9. Europe prostate cancer diagnostics market, BY product type
    1. overview
    2. reagents & consumables
    3. instruments
    4. accessories
  10. Europe prostate cancer diagnostics market, BY DIAGNOSTICS TYPE
    1. overview
    2. preliminary screening tests
      1. Prostate-Specific Antigen (PSA) Test
      2. Digital Rectal Exam (DRE) Test
    3. Confirmatory Tests
      1. PCA3 Test
      2. biopsy
      3. imaging tests
        1. ULTRASOUND
        2. MAGNETIC RESONANCE IMAGING (MRI)
          1. MULTIPARAMETRIC MRI
          2. MRI FUSION-GUIDED PROSTATE BIOPSY
        3. CT SCAN
        4. BONE SCAN
        5. PET/CT SCAN
      4. biomarker
        1. RNA BIOMARKERS
        2. DNA BIOMARKERS
        3. PROTEIN BIOMARKERS
  11. Europe prostate cancer diagnostics market, By type
    1. overview
    2. PROSTATIC ADENOCARCINOMA
    3. small cell carcinoma
    4. Others
  12. Europe prostate cancer diagnostics market, BY AGE GROUP
    1. overview
    2. geriatrics
    3. adult
    4. Pediatric
  13. Europe prostate cancer diagnostics market, BY Stage
    1. overview
    2. LOCALIZED PROSTATE CANCER
    3. RECURRENT/ADVANCED PROSTATE CANCER
    4. CASTRATION-RESISTANT PROSTATE CANCER (METASTATIC AND NON-METASTATIC)
  14. Europe prostate cancer diagnostics market, BY sample type
    1. overview
    2. Blood
    3. tissue
    4. urine
    5. others
  15. Europe prostate cancer diagnostics market, BY end users
    1. overview
    2. Independent Diagnostic Laboratories
    3. hospitals
    4. Clinics
    5. Ambulatory Surgical Centers
    6. Cancer Research Institutes
    7. others
  16. Europe prostate cancer diagnostics market, BY Distribution Channel
    1. overview
    2. direct tender
    3. retail sales
  17. Europe prostate cancer diagnostics market, BY Country
    1. GERMANY
    2. FRANCE
    3. u.k.
    4. iTALY
    5. SPAIN
    6. RUSSIA
    7. SWITZERLAND
    8. NETHERLANDS
    9. TURKEY
    10. bELGIUM
    11. REST OF EUROPE
  18. EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY landscape
    1. company share analysis: europe
  19. SWOT
  20. company profile
    1. F. Hoffmann-La Roche Ltd
      1. COMPANY SNAPSHot
      2. REVENUE ANALYSIS
      3. product Portfoli0
      4. RECENT DEVELOPMENTs
    2. Abbott
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    3. siemens HEALTHCARE gmbh
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    4. OPko HEALTH INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    5. Beckman Coulter, Inc. (A Subsidiary of Danaher)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    6. acon laboratories inc.
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
    7. Biomerieux sa
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENT
    8. Diasorin s.p.a
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLI0
      4. RECENT DEVELOPMENTS
    9. Eurolyser Diagnostica GmbH
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENT
    10. FUJIREBIO
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLI
      3. RECENT DEVELOPMENTS
    11. GENOMIC HEALTH, INC., (A SUBSIDIARY OF EXACT SCIENCES CORPORATION)
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    12. HOLOGIC, INC.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    13. MDXHEALTHCARE
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    14. Myraid genetics, inc.
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    15. Prostatype Genomics
      1. COMPANY SNAPSHOT
      2. REVENUE ANALYSIS
      3. PRODUCT PORTFOLIO
      4. RECENT DEVELOPMENTS
    16. PROTEOMEDIX
      1. COMPANY SNAPSHOT
      2. PRODUCT PORTFOLIO
      3. RECENT DEVELOPMENTS
  21. questionnaire
  22. related reports

Lista de Tablas

TABLE 1 AGE AND PROBABILITY OF DEVELOPING PROSTATE CANCER

TABLE 2 Europe prostate cancer diagnostics market, By product type, 2019-2028 (USD Million)

TABLE 3 Europe prostate cancer diagnostics market, By product type, 2019-2028 (UNits)

TABLE 4 Europe prostate cancer diagnostics market, By DIAGNOSTICS TYPE, 2019-2028 (USD Million)

TABLE 5 EUROPE preliminary screening tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 6 EUROPE Confirmatory tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 7 EUROPE imaging tests IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 8 EUROPE Magnetic Resonance Imaging (MRI) IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 9 EUROPE biomarker IN PROSTATE CANCER DIAGNOSTICS MARKET, By DIAGNOSTICS TYPE, 2019-2028 (USD million)

TABLE 10 Europe prostate cancer diagnostics market, By type, 2019-2028 (USD million)

TABLE 11 Europe prostate cancer diagnostics market, By age group, 2019-2028 (USD Million)

TABLE 12 Europe prostate cancer diagnostics market, By Stage, 2019-2028 (USD Million)

TABLE 13 Europe prostate cancer diagnostics market, By Sample Type, 2019-2028 (USD Million)

TABLE 14 Europe prostate cancer diagnostics market, By End Users, 2019-2028 (USD Million)

TABLE 15 Europe prostate cancer diagnostics market, By distribution channel, 2019-2028 (USD Million)

TABLE 16 Europe prostate cancer diagnostics market, By country, 2019-2028 (USD Million)

TABLE 17 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 18 GERMANY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 19 GERMANY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 20 GERMANY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 21 GERMANY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 22 GERMANY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 23 GERMANY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 24 GERMANY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 25 GERMANY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 26 GERMANY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 27 GERMANY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 28 GERMANY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 29 GERMANY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 30 GERMANY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 31 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 32 FRANCE Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 33 FRANCE Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 34 FRANCE Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 35 FRANCE Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 36 FRANCE Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 37 FRANCE Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 38 FRANCE Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 39 FRANCE Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 40 FRANCE Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 41 FRANCE Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 42 FRANCE Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 43 FRANCE Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 44 FRANCE Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 45 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 46 U.K. Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 47 U.K. Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 48 U.K. Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 49 U.K. Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 50 U.K. Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 51 U.K. Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 52 U.K. Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 53 U.K. Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 54 U.K. Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 55 U.K. Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 56 U.K. Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 57 U.K. Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 58 U.K. Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 59 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 60 ITALY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 61 ITALY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 62 ITALY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 63 ITALY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 64 ITALY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 65 ITALY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 66 ITALY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 67 ITALY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 68 ITALY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 69 ITALY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 70 ITALY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 71 ITALY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 72 ITALY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 73 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 74 SPAIN Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 75 SPAIN Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 76 SPAIN Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 77 SPAIN Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 78 SPAIN Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 79 SPAIN Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 80 SPAIN Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 81 SPAIN Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 82 SPAIN Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 83 SPAIN Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 84 SPAIN Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 85 SPAIN Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 86 SPAIN Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 87 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 88 RUSSIA Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 89 RUSSIA Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 90 RUSSIA Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 91 RUSSIA Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 92 RUSSIA Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 93 RUSSIA Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 94 RUSSIA Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 95 RUSSIA Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 96 RUSSIA Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 97 RUSSIA Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 98 RUSSIA Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 99 RUSSIA Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 100 RUSSIA Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 101 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 102 SWITZERLAND Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 103 SWITZERLAND Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 104 SWITZERLAND Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 105 SWITZERLAND Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 106 SWITZERLAND Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 107 SWITZERLAND Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 108 SWITZERLAND Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 109 SWITZERLAND Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 110 SWITZERLAND Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 111 SWITZERLAND Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 112 SWITZERLAND Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 113 SWITZERLAND Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 114 SWITZERLAND Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 115 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 116 NETHERLANDS Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 117 NETHERLANDS Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 118 NETHERLANDS Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 119 NETHERLANDS Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 120 NETHERLANDS Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 121 NETHERLANDS Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 122 NETHERLANDS Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 123 NETHERLANDS Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 124 NETHERLANDS Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 125 NETHERLANDS Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 126 NETHERLANDS Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 127 NETHERLANDS Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 128 NETHERLANDS Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 129 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 130 TURKEY Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 131 TURKEY Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 132 TURKEY Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 133 TURKEY Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 134 TURKEY Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 135 TURKEY Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 136 TURKEY Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 137 TURKEY Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 138 TURKEY Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 139 TURKEY Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 140 TURKEY Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 141 TURKEY Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 142 TURKEY Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 143 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (USD Million)

TABLE 144 BELGIUM Prostate Cancer Diagnostics Market, By Product Type, 2019-2028 (Units)

TABLE 145 BELGIUM Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 146 BELGIUM Preliminary Screening Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 147 BELGIUM Confirmatory Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 148 BELGIUM Imaging Tests in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 149 BELGIUM Magnetic Resonance Imaging (MRI) in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 150 BELGIUM Biomarker in Prostate Cancer Diagnostics Market, By Diagnostics Type, 2019-2028 (USD Million)

TABLE 151 BELGIUM Prostate Cancer Diagnostics Market, By Age Group, 2019-2028 (USD Million)

TABLE 152 BELGIUM Prostate Cancer Diagnostics Market, By Type, 2019-2028 (USD Million)

TABLE 153 BELGIUM Prostate Cancer Diagnostics Market, By Stage, 2019-2028 (USD Million)

TABLE 154 BELGIUM Prostate Cancer Diagnostics Market, By Sample Type, 2019-2028 (USD Million)

TABLE 155 BELGIUM Prostate Cancer Diagnostics Market, By End Users, 2019-2028 (USD Million)

TABLE 156 BELGIUM Prostate Cancer Diagnostics Market, By Distribution Channel, 2019-2028 (USD Million)

TABLE 157 rest of Europe prostate cancer diagnostics market, By Product Type, 2019-2028 (USD Million)

Lista de figuras

FIGURE 1 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: segmentation

FIGURE 2 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: data triangulation

FIGURE 3 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DROC ANALYSIS

FIGURE 4 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: regional VS country MARKET ANALYSIS

FIGURE 5 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MULTIVARIATE MODELLING

FIGURE 7 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 8 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID

FIGURE 9 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: MARKET end users coverage GRID

FIGURE 10 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 EUROPE PROSTATE CANCER DIAGNOSTICS MARKET: SEGMENTATION

FIGURE 12 INCREASING PREVALENCE OF PROSTATE CANCER and INCREASED RESEARCH & DEVELOPMENT IN PROSTATE CANCER DIAGNOSTICs are DRIVing THE EUROPE PROSTATE CANCER DIAGNOSTICS MARKET IN THE FORECAST PERIOD OF 2021 to 2028

FIGURE 13 REAGENTS & CONSUMABLES segment is expected to account for the largest share of the EUROPE PROSTATE CANCER DIAGNOSTICS MARKETin 2021 & 2028

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF EUROPE PROSTATE CANCER DIAGNOSTICS MARKET

FIGURE 15 GERIATRIC POPULATION IN THE EUROPEAN REGION

FIGURE 16 Europe prostate cancer diagnostics market : BY product type, 2020

FIGURE 17 Europe prostate cancer diagnostics market : BY product type, 2021-2028 (USD Million)

FIGURE 18 Europe prostate cancer diagnostics market : BY product type, CAGR (2021-2028)

FIGURE 19 PROSTATE CANCER DIAGNOSTICS market : BY product type, LIFELINE CURVE

FIGURE 20 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, 2020

FIGURE 21 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE 2021-2028 (USD Million)

FIGURE 22 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, CAGR (2021-2028)

FIGURE 23 Europe prostate cancer diagnostics market : BY DIAGNOSTICS TYPE, LIFELINE CURVE

FIGURE 24 Europe prostate cancer diagnostics market : By type, 2020

FIGURE 25 Europe prostate cancer diagnostics market : By type, 2021-2028 (USD Million)

FIGURE 26 Europe prostate cancer diagnostics market : By type, CAGR (2021-2028)

FIGURE 27 Europe prostate cancer diagnostics market : By type, LIFELINE CURVE

FIGURE 28 Europe prostate cancer diagnostics market : BY age group, 2020

FIGURE 29 Europe prostate cancer diagnostics market : BY age group, 2021-2028 (USD Million)

FIGURE 30 Europe prostate cancer diagnostics market : BY age group, CAGR (2021-2028)

FIGURE 31 Europe prostate cancer diagnostics market : BY age group, LIFELINE CURVE

FIGURE 32 Europe prostate cancer diagnostics market : BY stage, 2020

FIGURE 33 Europe prostate cancer diagnostics market : BY stage, 2021-2028 (USD Million)

FIGURE 34 Europe prostate cancer diagnostics market : BY stage, CAGR (2021-2028)

FIGURE 35 Europe prostate cancer diagnostics market : BY stage, LIFELINE CURVE

FIGURE 36 Europe prostate cancer diagnostics market : BY sample type, 2020

FIGURE 37 Europe prostate cancer diagnostics market : BY sample type, 2021-2028 (USD Million)

FIGURE 38 Europe prostate cancer diagnostics market : BY sample type, CAGR (2021-2028)

FIGURE 39 Europe prostate cancer diagnostics market : BY sample type, LIFELINE CURVE

FIGURE 40 Europe prostate cancer diagnostics market : BY end users, 2020

FIGURE 41 Europe prostate cancer diagnostics market : BY end users, 2021-2028 (USD Million)

FIGURE 42 Europe prostate cancer diagnostics market : BY end users, CAGR (2021-2028)

FIGURE 43 Europe prostate cancer diagnostics market : BY end users, LIFELINE CURVE

FIGURE 44 Europe prostate cancer diagnostics market : BY distribution channel, 2020

FIGURE 45 Europe prostate cancer diagnostics market : BY distribution channel, 2021-2028 (USD Million)

FIGURE 46 Europe prostate cancer diagnostics market : BY distribution channel, CAGR (2021-2028)

FIGURE 47 Europe prostate cancer diagnostics market : BY distribution, LIFELINE CURVE

FIGURE 48 Europe prostate cancer diagnostics market : SNAPSHOT (2020)

FIGURE 49 Europe prostate cancer diagnostics market : BY COUNTRY (2020)

FIGURE 50 Europe prostate cancer diagnostics market : BY COUNTRY (2021 & 2028)

FIGURE 51 Europe prostate cancer diagnostics market : BY COUNTRY (2020 & 2028)

FIGURE 52 Europe prostate cancer diagnostics market : BY Product type (2021-2028)

FIGURE 53 europe Prostate cancer diagnostics market: company share 2020 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Europe Prostate Cancer Diagnostics Market is projected to grow at a CAGR of 4.5% during the forecast period by 2028.
The future market value of the Europe Prostate Cancer Diagnostics Market is expected to reach USD 1,689,861.89 thousand by 2028.
The major players in the Europe prostate cancer diagnostics market are F. Hoffmann-La Roche Ltd, Siemens Healthcare GmbH, OPKO Health Inc., Abott, Beckman Coulter, Inc. (A Subsidiary of Danaher), among other domestic and global players.
The countries covered in the Europe prostate cancer diagnostics market are Germany, France, U.K., Italy, Spain, Russia, Turkey, Netherlands, Switzerland, Belgium and Rest of Europe.

Explorar páginas relacionadas

Banner